Because FBRA inhibits prostate cancer progression in TRAP rats, which lack functional p53 and RB tumor suppressors, the identified chemopreventive action of FBRA is specifically focused on delaying the development of clinically evident disease by suppressing the progression of precancerous lesions to prostate cancer. This evidence concerns the gene RB1 and prostate carcinoma.